Report Series Uncovers the Commercial Outlook for Currently Marketed Drugs and Drugs in Research and Development
Posted on: Thursday, 2 February 2006, 09:01 CST
WALTHAM, Mass., Feb. 2 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, announces a new electronic format for Pharmacor, the company's report series that uncovers the commercial outlook for currently marketed drugs and drugs in within reports, a robust search capability, and easy printing options.
"As the leader in pharmaceutical market research, it is important for us to continually evolve our products and services to complement how our clients want to work," said Sarah Fuller, President of Decision Resources, Inc. "After many conversations with our clients, it was clear that we could take Pharmacor to the next level by upgrading the ease-of-use and navigation within each report. We're confident that our clients will find these enhancements invaluable."
Pharmacor still offers the same level of in-depth information on specific indications. Each report includes epidemiology, etiology and pathophysiology, current therapies, medical practice, unmet clinical needs, emerging therapies, market outlook sections, as well as an Interactive Forecast Tool that can be used to build a seven-country market forecast based on Decision Resources' patient-based market models. Important new enhancements to Pharmacor include:
* Key tables and figures listed under separate drop-down menus * Quantitative tables that can be downloaded into Excel * Robust graphics * A "Key Findings" page for each chapter summarizing key points * Search capability within a report * Chapter-level and report-level easy printing options About Pharmacor from Decision Resources
Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for marketed drugs and drugs in research and development. Pharmacor covers diseases within the following therapeutic areas: cancer, cardiovascular, central nervous system, immune & inflammatory, infectious disease, genitourinary diseases, gastrointestinal diseases, pain management, respiratory diseases, and more.
About Decision Resources
Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their
All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.
For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com
First Call Analyst: FCMN Contact:
Decision Resources, Inc.
CONTACT: Elizabeth Marshall of Decision Resources, Inc.,+1-781-296-2563, emarshall@dresources.com
Web site: http://www.decisionresources.com/
Source: PRNewswire
Related Articles
- Mobile Marketing Association Announces Fourth Research Partner
- Bapineuzumab To Become the First-to-Market Disease-Modifying Alzheimer's Drug After Flurizan's Discontinuation
- EncounterPRO Healthcare Resources Announces Signing of Three New Clients
- Digital Media and Technology Investor Podcast With Gerry Kaufhold, Founder and Analyst at In-Stat's Converging Markets and Technologies Information Research Service
- GlaxoSmithKline's Coreg Will Be Prescribed More and More As a First Line Therapy for the Treatment of Chronic Heart Failure As Physicians' Comfort Level With the Drug Increases
- Decision Resources Defines a Hypothetical Parkinson's Disease Drug That Would Earn 25% Patient Share
- While Some Physicians Believe That Inhaled Corticosteroids Are Overused for the Treatment of Chronic Obstructive Pulmonary Disease, Majority Say the Drugs Help Treat the Disease
- HIV Stands Out As a Highly Lucrative and Expanding Market for Diagnostics Because of the Close Integration of Diagnostics in Day-to-Day Disease Diagnosis, Management and Drug Selection
- New Treatment Guidelines for Long-Neglected Peripheral Arterial Disease Will Drive the Drug Market
- Lung Experts Condemn Low Levels of Research Funding into Killer Disease
 |
 |
User Comments (0)
RSS Feeds